Back to results
US 2017/0362290 A1Published application
Il-17a-binding polypeptides
AssigneeAffibody AB
InventorsFredrik Frejd, Joachim Feldwisch, Susanne Klint, Lindvi Gudmundsdotter
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX2DX4AX6X7EIX10X11 LPNL X16X17X18QX20X21AFIX25 X26LX28X29. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.
Claims18
An IL-17A binding polypeptide, comprising an IL-17A binding motif BM, which motif consists of an amino acid sequence selected from:
- i) EX2DX4AX6X7EIX10X11LPNL X16X17X18QX20X21AFIX25 X26LX28X29
- wherein, independently from each other,
- X2 is selected from A, H, M and Y;
- X4 is selected from A, D, E, F, K, L, M, N, Q, R, S and Y;
- X6 is selected from A, Q and W;
- X7 is selected from F, I, L, M, V, W and Y;
- X10 is selected from A and W;
- X11 is selected from A, D, E, F, G, L, M, N, Q, S, T and Y;
- X16 is selected from N and T;
- X17 is selected from H, W and Y;
- X18 is selected from A, D, E, H and V;
- X20 is selected from A, G, Q, S and W;
- X21 is selected from A, D, E, F, H, K, N, R, T, V, W and Y;
- X25 is selected from A, D, E, G, H, I, L, M, N, Q, R, S, T and V;
- X26 is selected from K and S;
- X28 is selected from I, L, N and R;
- and
- X29 is selected from D and R;
- and
- ii) an amino acid sequence which has at least 89% identity to the sequence defined in i).
17 more elements
(canceled)
Dependencies are inferred from the claim text.